Lupin inches up on inking licensing pact with Gan & Lee Pharma for novel GLP-1 receptor agonist
Lupin is currently trading at Rs. 2082.90, up by 3.40 points or 0.16% from its previous closing of Rs. 2079.50 on the BSE.
The scrip opened at Rs. 2098.95 and has touched a high and low of Rs. 2099.60 and Rs. 2081.00 respectively. So far 5089 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 2403.45 on 02-Jan-2025 and a 52 week low of Rs. 1774.00 on 07-Apr-2025.
Last one week high and low of the scrip stood at Rs. 2116.90 and Rs. 2077.10 respectively. The current market cap of the company is Rs. 95267.67 crore.
The promoters holding in the company stood at 46.90%, while Institutions and Non-Institutions held 47.06% and 6.06% respectively.
Lupin has entered into an exclusive license, supply and distribution agreement with Gan & Lee Pharmaceuticals, headquartered in China, for a novel fortnightly GLP-1 receptor agonist, Bofanglutide. The agreement strengthens the company’s diabetes portfolio and accelerates its presence in the obesity segment. Bofanglutide injection is a fortnightly (once in two weeks) GLP-1 receptor agonist developed by Gan & Lee, intended for treating adults with type 2 diabetes and aiding weight management in overweight or obese individuals.
As a potential first-in-class global fortnightly GLP-1 agonist, clinical data demonstrate that the weight loss results of Bofanglutide are comparable to or better than those of existing GLP-1 alternatives while offering the convenience of once in two weeks versus once a week for other injectable alternatives, and maintaining safety and tolerability consistent with the GLP-1 class. It effectively reduces both blood glucose levels and body weight. Under the terms of the agreement, the company will have exclusive rights to commercialize and distribute Bofanglutide in India.
Lupin is an innovation led transnational pharmaceutical company producing, developing and marketing a wide range of branded and generic formulations, biotechnology products and active pharmaceutical ingredients (APIs) globally.
